Pharma Two B taking 'synergistic' approach in pursuit of 505(b)(2) approval

Israeli start-up Pharma Two B has taken the concept of synergism seriously, from the eclectic group of scientists and managers it has brought together under one roof, to its fixed-dose combination strategy of drug development, to the approval pathway it plans to seek in gaining the US FDA's OK – 505 (b)(2), a hybrid route to approval that is increasingly growing more popular in the US because of the costs saved and time reduced in getting medicines to the marketplace.

Pharma Two B's combined years of drug R&D and marketing experience, said CEO Dr Nurit Livnah, add up to over 100, which she noted is not bad for a...